Literature DB >> 27460089

Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.

Irena Marjanovic1, Jelena Kostic1, Bojana Stanic1, Nadja Pejanovic1, Bojana Lucic1, Teodora Karan-Djurasevic1, Dragana Janic2,3, Lidija Dokmanovic2,3, Srdja Jankovic2, Nada Suvajdzic Vukovic3,4, Dragica Tomin3,4, Ognjen Perisic5, Goran Rakocevic5, Milos Popovic5, Sonja Pavlovic1, Natasa Tosic6.   

Abstract

The age-specific differences in the genetic mechanisms of myeloid leukemogenesis have been observed and studied previously. However, NGS technology has provided a possibility to obtain a large amount of mutation data. We analyzed DNA samples from 20 childhood (cAML) and 20 adult AML (aAML) patients, using NGS targeted sequencing. The average coverage of high-quality sequences was 2981 × per amplicon. A total of 412 (207 cAML, 205 aAML) variants in the coding regions were detected; out of which, only 122 (62 cAML and 60 aAML) were potentially protein-changing. Our results confirmed that AML contains small number of genetic alterations (median 3 mutations/patient in both groups). The prevalence of the most frequent single gene AML associated mutations differed in cAML and aAML patient cohorts: IDH1 (0 % cAML, 5 % aAML), IDH2 (0 % cAML, 10 % aAML), NPM1 (10 % cAML, 35 % aAML). Additionally, potentially protein-changing variants were found in tyrosine kinase genes or genes encoding tyrosine kinase associated proteins (JAK3, ABL1, GNAQ, and EGFR) in cAML, while among aAML, the prevalence is directed towards variants in the methylation and histone modifying genes (IDH1, IDH2, and SMARCB1). Besides uniform genomic profile of AML, specific genetic characteristic was exclusively detected in cAML and aAML.

Entities:  

Keywords:  Adult AML; Childhood AML; Next generation sequencing; SNVs

Mesh:

Substances:

Year:  2016        PMID: 27460089     DOI: 10.1007/s13277-016-5142-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 4.  Acute myeloid leukaemia in the elderly: a review.

Authors:  Daniel A Pollyea; Holbrook E Kohrt; Bruno C Medeiros
Journal:  Br J Haematol       Date:  2011-03       Impact factor: 6.998

5.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

Review 7.  Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Authors:  Brunangelo Falini; Paolo Sportoletti; Maria Paola Martelli
Journal:  Curr Opin Oncol       Date:  2009-11       Impact factor: 3.645

8.  Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.

Authors:  D H Kim; W Xu; S Kamel-Reid; X Liu; C W Jung; S Kim; J H Lipton
Journal:  Ann Oncol       Date:  2009-10-29       Impact factor: 32.976

9.  IDH1 and IDH2 mutations in pediatric acute leukemia.

Authors:  A K Andersson; D W Miller; J A Lynch; A S Lemoff; Z Cai; S B Pounds; I Radtke; B Yan; J D Schuetz; J E Rubnitz; R C Ribeiro; S C Raimondi; J Zhang; C G Mullighan; S A Shurtleff; B A Schulman; J R Downing
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 12.883

10.  DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.

Authors:  Timothy J Ley; Elaine R Mardis; Li Ding; Bob Fulton; Michael D McLellan; Ken Chen; David Dooling; Brian H Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E Larson; Dan C Koboldt; Craig Pohl; Scott Smith; Amy Hawkins; Scott Abbott; Devin Locke; Ladeana W Hillier; Tracie Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua Conyers; Nathan Sander; Xiaoqi Shi; John R Osborne; Patrick Minx; David Gordon; Asif Chinwalla; Yu Zhao; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark Watson; Jack Baty; Jennifer Ivanovich; Sharon Heath; William D Shannon; Rakesh Nagarajan; Matthew J Walter; Daniel C Link; Timothy A Graubert; John F DiPersio; Richard K Wilson
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

View more
  3 in total

1.  Discovery of cancer common and specific driver gene sets.

Authors:  Junhua Zhang; Shihua Zhang
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

2.  Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia.

Authors:  Dragana Janic; Jelena Peric; Teodora Karan-Djurasevic; Tatjana Kostic; Irena Marjanovic; Bojana Stanic; Nadja Pejanovic; Lidija Dokmanovic; Jelena Lazic; Nada Krstovski; Marijana Virijevic; Dragica Tomin; Ana Vidovic; Nada Suvajdzic-Vukovic; Sonja Pavlovic; Natasa Tosic
Journal:  J Med Biochem       Date:  2020-01-10       Impact factor: 3.402

3.  A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

Authors:  D A Casolari; T Nguyen; C M Butcher; D G Iarossi; C N Hahn; S C Bray; P Neufing; W T Parker; J Feng; K Z Y Maung; A Wee; L Vidovic; C H Kok; P G Bardy; S Branford; I D Lewis; S W Lane; H S Scott; D M Ross; R J D'Andrea
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.